retatrutide 2025 trial results 28.7% Weight Loss in New Study – Dr Brad Stanfield Eli Lilly and Company Stock

It is particularly valuable for researchers studying the interplay between glucagon signaling, hepatic lipid oxidation, and thermogenesis -- areas where single- and dual-agonists provide limited data

However, Retatrutide is not yet Health Canada approved, with expected regulatory decisions coming in late 2026 or early 2027

Certain bacterial strains stimulate L-cells to produce more GLP-1 naturally

At $149-$299 per month for oral Wegovy without insurance, annual costs range from approximately $1,788 to $3,588

Biomol Concepts

The FDA has explicitly stated that retatrutide cannot be used in compounding under federal law because it is not a component of an FDA-approved drug and has not been evaluated for safety and efficacy